Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
Status:
Withdrawn
Trial end date:
2020-02-03
Target enrollment:
Participant gender:
Summary
This study will investigate whether the use of talimogene laherparepvec (T-VEC) in
combination with BRAF/MEK inhibitor will result in durable regional and distant recurrence
free survival in the neoadjuvant setting for treatment of advanced nodal BRAF mutant
melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Angela N Fellner PhD CCRP TriHealth Inc.
Collaborators:
Bethesda North TriHealth Hospital Good Samaritan TriHealth Hospital TriHealth Cancer Institute TriHealth Surgical Institute TriHealth Ultrasound Department